[CAR-T therapy for adult B-cell acute lymphoblastic leukemia].
Rinsho Ketsueki
; 64(11): 1432-1439, 2023.
Article
en Ja
| MEDLINE
| ID: mdl-38072431
ABSTRACT
Although adult B-cell acute lymphoblastic leukemia (B-ALL) responds to initial treatment, relapse and refractory cases are common. Even when these cases are treated with novel agents (blinatumomab, inotuzumab ozogamicin, etc.) and/or allogeneic stem cell transplantation, the prognosis remains poor. Recently, chimeric antigen receptor T-cell (CAR-T) therapy, targeting CD19, has demonstrated great potential in treating relapsed or refractory B-ALL. We have already used tisagenlecleucel in clinical practice, but it is limited to patients up to 25 years of age. This review summarizes the most recent evidence on CAR-T therapy for relapsed or refractory adult B-ALL, which has a poor prognosis when assessed in younger patients.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trasplante de Células Madre Hematopoyéticas
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Receptores Quiméricos de Antígenos
Límite:
Adult
/
Humans
Idioma:
Ja
Revista:
Rinsho Ketsueki
Año:
2023
Tipo del documento:
Article